Trial · NCT03539432
Exploration of Gemfibrozil as a Treatment for AUD
NCT03539432, Phase 2, Terminated, The Mind Research Network; results first posted 2021-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Exploration of Gemfibrozil as a Treatment for AUD. Trials, record NCT03539432. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03539432
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Exploration of Gemfibrozil as a Treatment for AUD
- NCT number
- NCT03539432
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- The Mind Research Network
- Conditions
- Alcohol Use Disorder
- Interventions
- Gemfibrozil 600 MG, Placebo oral capsule
- First posted
- 2018-05-29
- Last updated
- 2021-10-29
- Results first posted
- 2021-10-18
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Standard Drinks Per Drinking Day | Baseline | Average number of standard drinks consumed on drinking days |
| Primary | Mean Standard Drinks Per Drinking Day | 2 weeks post baseline | Average number of standard drinks consumed on drinking days |
| Primary | Mean Standard Drinks Per Drinking Day | 4 weeks post baseline | Average number of standard drinks consumed on drinking days |
| Primary | Percent Days Abstinent | Baseline | Percentage of days of abstinence from alcohol |
| Primary | Percent Days Abstinent | 2 weeks post baseline | Percentage of days of abstinence from alcohol |
| Primary | Percent Days Abstinent | 4 weeks post baseline | Percentage of days of abstinence from alcohol |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Standard Drinks Per Drinking Day | Baseline | Drinks per drinking day | MEAN | |
| PRIMARY | Mean Standard Drinks Per Drinking Day | 2 weeks post baseline | The one participant in the placebo condition dropped out before taking any medication | Drinks per drinking day | MEAN |
| PRIMARY | Mean Standard Drinks Per Drinking Day | 4 weeks post baseline | The one participant in the placebo condition dropped out before taking any medication | Drinks per drinking day | MEAN |
| PRIMARY | Percent Days Abstinent | Baseline | Percentage of abstinent days | MEAN | |
| PRIMARY | Percent Days Abstinent | 2 weeks post baseline | The one participant in the placebo condition dropped out before taking any medication | Percentage of abstinent days | MEAN |
| PRIMARY | Percent Days Abstinent | 4 weeks post baseline | The one participant in the placebo condition dropped out before taking any medication | Percentage of abstinent days | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Standard Drinks Per Drinking Day | Gemfibrozil | 6.17 | Full Range 5.57 to 6.76 | Drinks per drinking day | |
| Mean Standard Drinks Per Drinking Day | Placebo | 8.59 | Full Range 8.59 to 8.59 | Drinks per drinking day | |
| Mean Standard Drinks Per Drinking Day | Gemfibrozil | 4.12 | Full Range 3.58 to 4.667 | Drinks per drinking day | |
| Mean Standard Drinks Per Drinking Day | Gemfibrozil | 2.18 | Full Range 2 to 2.35 | Drinks per drinking day | |
| Percent Days Abstinent | Gemfibrozil | 31 | Full Range 16.7 to 44.4 | Percentage of abstinent days | |
| Percent Days Abstinent | Placebo | 32.2 | Full Range 32.2 to 32.2 | Percentage of abstinent days | |
| Percent Days Abstinent | Gemfibrozil | 45.5 | Full Range 0 to 90.9 | Percentage of abstinent days | |
| Percent Days Abstinent | Gemfibrozil | 45 | Full Range 0 to 90 | Percentage of abstinent days |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Gemfibrozil | 2 | |
| Overall Study | STARTED | Placebo | 1 | |
| Overall Study | COMPLETED | Gemfibrozil | 2 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Gemfibrozil | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Gemfibrozil | 1 | 2 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Placebo | 0 | 1 | 0 |
| other | Fatigue | Nervous system disorders | Gemfibrozil | 1 | 2 | 1 |
| other | Fatigue | Nervous system disorders | Placebo | 0 | 1 | 0 |
| other | Bruising | Skin and subcutaneous tissue disorders | Gemfibrozil | 1 | 2 | 1 |
| other | Bruising | Skin and subcutaneous tissue disorders | Placebo | 0 | 1 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Gemfibrozil | 0 | 2 |
| Total, all-cause mortality | Placebo | 0 | 1 |
| Total, other adverse events | Gemfibrozil | 1 | 2 |
| Total, other adverse events | Placebo | 0 | 1 |
| Total, serious adverse events | Gemfibrozil | 0 | 2 |
| Total, serious adverse events | Placebo | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Gemfibrozil vs Placebo: deaths from any cause | Trial comparisons |
| Gemfibrozil vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03539432
GET https://conductscience.org/api/trials/v1/NCT03539432/registered